Research and Markets: Laquinimod (Multiple Sclerosis) – Forecast and Market Analysis to 2022

SummaryGlobalData has released its new PharmaPoint Drug Evaluation report, “Laquinimod (Multiple Sclerosis) – Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFNß) agents: Bayer’s Betaseron/Betaferon (IFNß-1b), Biogen’s Avonex (IFNß-1a) and Merck’s Rebif (IFNß-1a), and Teva’s Copaxone (glatiramer acetate), has been a salient feature of the MS therapeutics market. However, the competitive landscape is undergoing significant change with the emergence of oral therapies, several pipeline products with notable efficacies, and looming generics/biosimilars following the patent expiries of key branded products during the forecast period. In addition, the entry of new companies such as Sanofi/Genzyme and F. Hoffmann-La-Roche/Genentech will challenge the position of the established players in the MS marketplace.Teva’s and Active Biotech’s laquinimod (ABR-215062) is a synthetic, once-daily, orally-administered immunomodulator under investigation for the treatment of RRMS. It is related to, but chemically distinct from, linomide (Roquinimex; Active Biotech); an experimental agent that had demonstrated some efficacy in the treatment of MS, but clinical testing was prematurely terminated because of serious cardiopulmonary toxicity.Scope– Overview of Multiple Sclerosis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.– Detailed information on Laquinimod including product description, safety and efficacy profiles as well as a SWOT analysis.– Sales forecast for Laquinimod for the top ten countries from 2012 to 2022.– Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Canada, China and India


source: http://www.researchandmarkets.com/research/jrn3cv/laquinimod

..